2013-03-02 16:05:43 - Financial Benchmarking, Pipeline Assessment & Competitive Analysis of Innovative Biotechs

The Innovative Mid-Cap Biotech Benchmark Report applies GlobalData's proprietary ranking methodology to compare the competitive position of 15 innovative biotech companies on 20 financial metrics. The performances of these companies are analyzed on financial performance, cost-containment, capital structure and firm utilization to illustrate the different strategies these companies are using to increase value for their shareholders. Throughout the report, GlobalData's analysts provide you with expert insight, expanding on each of the metrics discussed. In addition to the financial metrics, this report discusses each company's recent pipeline and clinical advancements, along with licensing and acquisition activity, and operations strategy. Lastly, this report provides GlobalData's viewpoint on each company's future revenue outlook, and competitive position within the biotech space.


Full Report Details at

- www.fastmr.com/prod/544327_pharmaleaders_innovative_midcap_biote ..


Scope

* Financial Benchmarking: Report uses GlobalData's proprietary benchmarking methodology to rank 15 innovative biotech companies on 20 different financial metrics
* Pipeline analysis: Tracks pipeline advancements and drug approvals across this peer group over the past 12 months
* Licensing & Acquisition Strategies: Deep discussion on the strategic implications and synergies of recent M&A and deals activity
* Resource Management Strategies: New section created to discuss and analyze the operations and firm utilization of these innovative biotech companies.
* Expert Insight on the corporate strategies of these mid-cap biotech companies seeking a competitive advantage in the pharmaceuticals market place
* Revenue Forecasts: New analysis providing top-line revenue forecast for each company for next six months.

Reasons to buy

* Analyze and track the strategies that these successful biotech companies are using to gain share in an increasingly competitive market
* Understand and benchmark the financial metrics that differentiate certain companies from the pack in terms of revenue performance, cost containment, and firm utilization
* Target novel companies with proprietary technologies to maximize opportunities for strategic investment or partnerships
* Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
* Use information as an independent source for your due diligence and transaction strategies.
* Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Partial Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Report Scope
2.2 Report Catalysts
2.3 Upcoming Related Reports
2.4 Recently Published Reports
2.5 GlobalData's Benchmarking Methodology
2.6 GlobalData 3Q12 Biotech Benchmark Leader: Regeneron
2.7 Regeneron Overtook Alexion in 3Q12 as Benchmark Leader
3 Financial Management
3.1 Competitive Framework
3.2 Overview
3.2.1 Biotech companies position themselves for revenue growth with higher sales, but will need to focus on cost containment to improve profit margins
3.3 Financial Management: Heat Map
3.3.1 Regeneron was the financial management leader in 3Q12, posting significantly higher scores across all metrics compared to its peer group
3.4 Financial Metrics
3.4.1 Revenue
3.4.2 Revenue Growth YtY
3.4.3 Operating Income
3.4.4 Operating Income Growth YtY
3.4.5 Operating Margin
3.5 Expense Management: Heat Map
3.5.1 ViroPharma was the expense management leader in 3Q12 due to manufacturing issues
3.6 Expense Metrics
3.6.1 R&D Expense as a Percentage of Revenue
3.6.2 R&D Spend Growth YtY
3.6.3 S,G&A Expenses as a Percentage of Revenue
3.6.4 S,G&A Spend Growth YtY
3.6.5 Total OpEx as a Percentage of Revenue
4 Pipeline Assessment
4.1 Overview
4.1.1 Despite its high cost, biotech companies are still investing in oncology
4.1.2 Big Pharma's exit from CNS creates an opportunity for smaller players
4.2 GlobalData Pipeline Matrix and Competitive Positioning
4.2.1 Quadrant Analysis: Best-In-Class Assessment: Regeneron
4.2.2 Quadrant Analysis: Challengers Assessment: Jazz
4.2.3 Quadrant Analysis: Laggards Assessment: Exelixis
4.2.4 Quadrant Analysis: Innovators Assessment: Momenta
4.3 Pipeline Development
4.4 Clinical Highlights by Company
4.4.1 Acorda
4.4.2 Alexion
4.4.3 Alkermes
4.4.4 BioMarin
4.4.5 Cubist
4.4.6 Exelixis
4.4.7 Incyte
4.4.8 Jazz
4.4.9 Momenta
4.4.10 Nektar
4.4.11 Onyx
4.4.12 Regeneron
4.4.13 Seattle
4.4.14 United
4.4.15 ViroPharma
5 Licensing & Acquisition Strategies
5.1 Competitive Framework
5.2 Overview
5.3 M&A Analysis
5.3.1 Alkermes Acquisition of Elan Drug Technology Creates Leadership in CNS Therapeutics
5.3.2 Jazz Acquisition of EUSA Pharma Expands its Product Line to Include High-Margin Cancer Therapies
5.3.3 Alexion Adds to its Ultra-Rare Disease Portfolio through Acquisition
5.3.4 Jazz Purchase of Azur Complements its Pipeline in CNS and Women's Health
6 Resource Management Strategies
6.1 Competitive Framework
6.2 Overview
6.3 Operations & Supply Chain
6.3.1 Acorda Relocates Corporate HQ to Ardsley Park Life Sciences Campus
6.3.2 Cubist Expands Research & Development Facility
6.3.3 Jazz Sells Women's Health Business to Meda
6.3.4 Nektar Consolidates Research Assets to its R&D Center in San Francisco, CA
6.3.5 Regeneron Expands Greenbush Plant to Support its Antibody Clinic
6.3.6 ViroPharma Adds Manufacturing Scale to Cinryze Production to Meet Expected Demand
6.4 Resource Management: Heat Map
6.4.1 Cubist was the resource management leader in 3Q12, balancing spending & headcount with revenue growth
6.5 Firm Utilization Metrics

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=544327&dt=t

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.